Market: NMS |
Currency: USD
Address: 360 Massachusetts Avenue
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 test for the monitoring of disease progression in critical care settings. Further, it develops cardiac biomarkers, such as hsTNT and NT pro-BNP, as well as other tests using the Symphony platform. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Show more
📈 Bluejay Diagnostics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
10-25%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Bluejay Diagnostics, Inc.
| Date | Reported EPS |
|---|
| 2024-03-28 | -2848 |
| 2023-11-09 | -3328 |
| 2023-08-14 | -4400 |
📰 Related News & Research
-
Bluejay Diagnostics Nears Completion of SYMON-II Clinical Trial with 624 Patient Enrollments for Symphony IL-6 Sepsis Test
April 7, 2026
Bluejay Diagnostics Reaches Key Enrollment Milestone in SYMO...
-
Bluejay Diagnostics, Inc. Enters Securities Purchase Agreement for $25,000 Private Placement of Common Stock
March 18, 2026
Bluejay Diagnostics, Inc. Announces Private Placement with B...
-
Bluejay Diagnostics Evaluates Potential Acquisition Opportunity While Prioritizing Core Critical Care Platform Initiatives
March 16, 2026
Bluejay Diagnostics Responds to Shareholder Proposal Regardi...
-
Bluejay Diagnostics 2026 Annual Report: Symphony Platform, FDA Progress, Risks, and Business Overview
March 7, 2026
Bluejay Diagnostics, Inc. 2025 Annual Report: Key Highlights...
🔍 View more Reports